Cent Eur J Public Health 2006, 14(1):6-9 | DOI: 10.21101/cejph.b0051

The Evaluation of Short and Long Term Administration of Drugs Improving Life Expectancy in Patients with Myocardial Infarction in a Hungarian County Hospital

László Márk, Győző Dani, Erzsébet Nagy, Ferenc Erdei, András Katona
Department of Internal Medicine II - Cardiology, Pándy Kálmán Békés County Hospital, Gyula, Hungary

Objective: The patients after myocardial infarction could hope for a significant improvement in their life expectancy when complying with the principles of the secondary prevention. Today there is no doubt that the administration of ACE-inhibitors, beta-blockers, aspirin and statins decrease mortality in these patients. Although the clinicians are aware of the guidelines of Evidence Based Medicine, international and Hungarian surveys show that in their everyday application there is still much to improve.

Patients and methods: The authors studied the therapy of 200 consecutive patients (115 men and 85 women) who suffered from acute myocardial infarction (either STAMI or NSTAMI) in 1999-2000 at the discharge from their internal medicine department with cardiological profile and 6 months later during outpatient check-up. Having these therapeutic data a special emphasise was given to the same group of drugs and their administration was investigated in patients suffering from acute coronary syndrome with elevated troponin-T levels in the year 2002.

Results: In the study of years 1999-2000 at the discharge 175 of 200 patients received ACE-inhibitor (87%), 121 (60%) beta-blocker, 180 (90%) antiplatelet and 102 (51%) statin therapy. At the time of the control performed 6 months later 85% of the patients were on ACE-inhibitor, 88% on beta-blocker, 77% on aspirin and 47% on statin therapy. In this high risk population during the 6 months control the LDL-cholesterol goal of 2.5 mmol/l was attained in the 17% of patients. In the survey performed in 2002 the use of beta-receptor blocker increased to 85%, antiplatelet drug and statin administration to 95% and 57%, respectively.

Conclusions: Although the administration of drugs improving life expectancy in the authors' department is comparable with the published Hungarian and international data, effort to the widespread application of the ever growing principles of the Evidence Based Medicine and continuous self-control are essential.

Klíčová slova: acute myocardial infarction, secondary prevention, statins, antiplatelet therapy, Evidence Based Medicine

Vloženo: 30. květen 2005; Zveřejněno: 1. březen 2006  Zobrazit citaci

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Márk L, Dani G, Nagy E, Erdei F, Katona A. The Evaluation of Short and Long Term Administration of Drugs Improving Life Expectancy in Patients with Myocardial Infarction in a Hungarian County Hospital. Cent Eur J Public Health. 2006;14(1):6-9. doi: 10.21101/cejph.b0051. PubMed PMID: 16705873.
Stáhnout citaci

Reference

  1. Józan P. New trends in mortality and life expectancy: epidemiologic transition in Hungary? Orv Hetil. 2003 Mar 9;144(10):451-60. (In Hungarian.) Přejít na PubMed...
  2. Máchová L, Janout V. The incidence of acute myocardial infarction in the district Olomouc in 1994 - descriptive study. Cent Eur J Public Health. 1997 Sep;5(3):122-6.
  3. Komárek L, Rážová J, Pivničková M, Vignerová J, Roth Z, Ošancová K, Šoltysová T, Anděl M, Poledne R. Indicators of risk of ischaemic heart disease in patients with acute myocardial infarction under 65 years and their relatives. Cent Eur J Public Health. 1998 Aug;6(3):202-10.
  4. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, Wang CH, Heiss G. Trends in the incidence of myocardial infarction in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 1998 Sep 24;339(13):861-7. Přejít k původnímu zdroji... Přejít na PubMed...
  5. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J. Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Setchem U, Silber S, Thomsen T, Wood D; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003 Sep;24(17):1601-10. Přejít k původnímu zdroji...
  6. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R; ISIS-2 Collaborative Group. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ. 1998 May 2;316(7141):1337-43. Přejít k původnímu zdroji... Přejít na PubMed...
  7. Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention or death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86. Přejít k původnímu zdroji... Přejít na PubMed...
  8. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA. 1993 Oct 6;270(13):1589-95. Přejít k původnímu zdroji... Přejít na PubMed...
  9. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986 Jul 12;2(8498):57-66. Přejít k původnímu zdroji...
  10. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J. 1985 Mar;6(3):199-226. Přejít k původnímu zdroji...
  11. ISIS 4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995 Mar 18;345(8951):669-85. Přejít k původnímu zdroji...
  12. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993 Oct 2;342(8875):821-8. Přejít k původnímu zdroji...
  13. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC; The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival ventricular enlargement trial. N Engl J Med. 1992 Sep 3;327(10):669-77. Přejít k původnímu zdroji... Přejít na PubMed...
  14. Smith SC, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Kruss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2001 Nov 1;38(5):1581-3. Přejít k původnímu zdroji...
  15. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383-9. Přejít k původnímu zdroji...
  16. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996 Oct 3;335(14):1001-9. Přejít k původnímu zdroji... Přejít na PubMed...
  17. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998 Nov 5; 339(19):1349-57. Přejít k původnímu zdroji...
  18. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18(4):220-8.
  19. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001 Apr 1;87(7):819-22. Přejít k původnímu zdroji...
  20. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J. 1997 Oct;18(10):1569-82. Přejít k původnímu zdroji... Přejít na PubMed...
  21. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001 Apr;22(7):554-72. Přejít k původnímu zdroji... Přejít na PubMed...
  22. Östör E, Jánosi A, Ádám Z, Bárczy Gy, Borbás S, Dávid B, Gallai I, Podmaniczky M, Ruzsányi T. Secondary prevention of coronary disease - at the turn of the millennium in light of the Hungarian data of the EUROASPIRE I-II Studies. Orv Hetil. 2003 Dec 7; 144(49):2399-404. (In Hungarian.) Přejít na PubMed...
  23. Hasdai D, Behar S, Walletin L, Danchin N, Gitt E, Boerjma E, Fioretti PM, Simons ML, Battler A. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes. Eur Heart J. 2002 Aug;23(15):1190-201. Přejít k původnímu zdroji... Přejít na PubMed...
  24. Zöllei É, Paprika D, Vincze D, Rudas L. Quality assessment in the management of acute coronary syndromes. Lege Art Med. 2002;12 (8):488-92.
  25. Vale MJ, Jelinek MV, Best JD, Santamaria JD. Coaching patients with coronary heart disease to achieve target cholesterol: a method to bridge the gap between evidence-based medicine and the "real world" - randomised controlled trial. J Clin Epidemiol. 2002 Mar;55(3):245-52. Přejít k původnímu zdroji...
  26. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001 Mar 31;357(9261):995-1001. Přejít k původnímu zdroji...
  27. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assesment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000 Feb 28;160(4):459-67. Přejít k původnímu zdroji...
  28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. Přejít k původnímu zdroji... Přejít na PubMed...
  29. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Royal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-1504. Přejít k původnímu zdroji... Přejít na PubMed...